EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026edgewisetx.com
EWTX8:30 AMEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipelineedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com